Prime Editing and CRISPR Market Set for Explosive Growth at 24.1% CAGR During 2024-2031, Led by North America's 34.5% Market Share | Key Players - Beam Therapeutics, GenScript Biotech, ThermoFisher Scientific Inc

The Global Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031).

Market growth is driven by surging demand for precise gene editing therapies, expanding applications in rare genetic disorders and oncology, and promising clinical trial results demonstrating superior accuracy over traditional CRISPR-Cas9. Rapid advancements in delivery technologies like lipid nanoparticles, rising investments from biotech giants such as CRISPR Therapeutics and Editas Medicine, supportive FDA approvals for investigational therapies, and growing partnerships between pharma companies and gene editing startups are propelling the market forward.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/prime-editing-and-crispr-market?ram

Key Industry Developments

United States:
✅ January 2026: Prime Medicine announced positive Phase I/II data for prime editing in chronic granulomatous disease (CGD), marking first human results with improved safety and precision over traditional CRISPR.

✅ November 2025: CRISPR Therapeutics reported one-time therapy results targeting ANGPTL3 for cholesterol reduction in early human trial, expanding CRISPR applications to cardiovascular diseases.

✅ October 2025: U.S. FDA unveiled a "plausible mechanism" pathway to accelerate approvals for personalized CRISPR and prime editing therapies for ultra-rare diseases.

Asia Pacific / Japan:
✅ January 2026: MPM BioPharma launched CRISPR-edited rice variety optimized for higher yields and flood resistance in AgTech applications.

✅ October 2025: RIKEN launched CRISPR-based innovation for virus-resistant tomatoes, approved under Japan's relaxed bio-regulations.

✅ November 2025: SinoGene (China) secured NMPA approval milestone for CRISPR therapy against Duchenne muscular dystrophy.

Strategic Mergers and Acquisitions:
✅ Eli Lilly acquired Verve Therapeutics for up to $1.3 billion in June 2025, enhancing its CRISPR-based gene editing pipeline for cardiovascular therapies targeting PCSK9 and high cholesterol.

✅ GenScript Biotech signed a licensing agreement with the Broad Institute of MIT and Harvard in March 2025 to access prime editing technology, bolstering its gene-editing research and development capabilities.

Key Players:
Beam Therapeutics | GenScript Biotech | Horizon Discovery | Integrated DNA Technologies | Inscripta | Precision BioSciences | Thermo Fisher Scientific Inc. | Lonza Group

Strategic Leadership Report: Top 5 Players in Prime Editing and CRISPR Market 2026
-Beam Therapeutics: Advanced BEAM-302 for alpha-1 antitrypsin deficiency (AATD) with FDA-aligned accelerated approval pathway based on biomarker data from Phase 1/2 trials, demonstrating first in vivo genetic correction for liver and lung disease; progressed BEAM-301 for glycogen storage disease type Ia with dosing complete in initial cohorts and data expected mid-2026.

-GenScript Biotech: Launched GMP-like mRNA manufacturing service for preclinical and IND-enabling studies, enhancing LNP engineering for liver cell prime editing and targeted delivery in genetic therapies; introduced FLASH Gene service as the fastest sequence-to-plasmid solution to accelerate synthetic biology workflows.

-Integrated DNA Technologies: Expanded translational CRISPR portfolio with new high-purity offerings, off-target analysis services, and end-to-end solutions bridging discovery to clinical applications; unveiled PrimeTime Influenza Kit and Research Pathogen Panels to support infectious disease surveillance and biomarker discovery.

-Precision BioSciences: Advanced ARCUS nuclease platform with in vivo prime editing capabilities for liver-directed therapies, including preclinical data on enhanced precision and reduced off-target effects; launched next-generation gene editing services for custom therapeutic development in genetic diseases.

-Thermo Fisher Scientific: Introduced expanded CRISPRoff and CRISPRko portfolios with high-fidelity Cas9 variants for prime editing applications, improving indel-free base corrections; rolled out Gibco CTS TrueFect for GMP-grade lipid nanoparticles optimized for in vivo prime editing delivery in clinical-stage programs.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=prime-editing-and-crispr-market?ram

Market Drivers and Key Trends:
-Therapeutic Advancements: Prime editing enables precise, scarless DNA modifications without double-strand breaks, surpassing CRISPR-Cas9 limitations for treating genetic disorders like sickle cell disease and cystic fibrosis.

-Investment Surge: Rising funding from biotech firms, governments, and pharma giants fuels R&D, with the market valued at USD 10.85 billion in 2025 and growing at 11-13% CAGR through 2031.

-Precision Agriculture: CRISPR and prime editing enhance crop resilience, yield, and nutrition, addressing food security amid climate challenges.​

-AI Integration: Machine learning optimizes editing efficiency, reduces off-target effects, and accelerates personalized medicine pipelines.

-Regulatory Momentum: Approvals for clinical trials and therapies expand commercialization in healthcare and beyond.​

-Market Hurdles: Persistent off-target risks, high development costs, ethical concerns, and stringent IP regulations constrain broader adoption.​

Regional Insights:
-North America holds the largest share of the Prime Editing and CRISPR market at 34.5%, driven by advanced R&D infrastructure, key biotech players, and high genetic disease prevalence.

-Asia Pacific follows with 28.2%, exhibiting the fastest growth due to expanding research labs, rising chronic disease rates, and investments in China and India.

-Europe accounts for 22.1%, supported by steady funding for gene therapies and regulatory advancements.​

-Latin America and Middle East & Africa (LAMEA) represent 15.2% combined, emerging through infrastructure investments and novel drug demand.

Market Opportunities & Challenges: Prime Editing and CRISPR Market 2026
-Opportunities: A "Precision Therapeutics Surge" accelerates clinical pipelines; base and prime editing advancements enable scarless mutations for rare diseases. FDA fast-track designations and NIH-funded consortia for "multiplex editing" platforms de-risk investments in neuromuscular and oncology therapies.

-Challenges: "Off-Target Effect Legacy" scrutiny heightens regulatory delays, while IP thickets from Casgevy precedents fragment licensing deals. Success demands mastering vector immunogenicity hurdles and harmonizing global bioethics standards.

-Strategic Verdict: High-fidelity prime editors and in vivo delivery systems propel therapeutic dominance for 2026.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/prime-editing-and-crispr-market?ram

Market Segmentation Analysis:
-By Service: Gene Editing Leads with Precision Demand
Gene editing commands 45% market share in 2025, enabling targeted DNA modifications for therapeutic development in diseases like sickle cell anemia.
Cell line engineering follows at 25%, crucial for creating stable models in drug screening and biotech R&D.
Genome regulation holds 15%, focusing on epigenetic control for gene expression without cuts.
Gene-modified cell therapy and others split 15%, advancing personalized treatments but limited by high complexity and regulatory hurdles.

-By Application: Biomedical Research & Therapy Dominates Innovation
Biomedical research & therapy seizes 60% share, powering clinical trials and therapies for cancer, genetic disorders via precise edits.
Agricultural research captures 25%, enhancing crop resilience and yield through GMO advancements.
Others account for 15%, including industrial biotech and diagnostics with emerging potential.

-By End-User: Biotech & Pharma Companies Command Scale
Biotechnology & pharma companies lead at 50% share, investing heavily in proprietary editing platforms for drug pipelines.
Academic institutes hold 25%, driving foundational research and proof-of-concept studies.
Contract research organizations take 15%, offering outsourced expertise for efficiency.
Others claim 10%, spanning government labs and startups.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.